# DSIP Peptide FAQ: Frequently Asked Questions

> Answers to frequently asked questions about DSIP peptide — mechanism, sleep effects, dosage, safety, comparisons — drawn from the peer-reviewed research literature.

## DSIP peptide frequently asked questions

**What is DSIP peptide?**
DSIP (Delta Sleep-Inducing Peptide, also called emideltide) is a naturally occurring nonapeptide — nine amino acids: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu — isolated from the cerebral venous blood of sleeping rabbits. It is found endogenously in humans, primarily in a phosphorylated form (DSIP-P), and has been studied for sleep regulation, stress modulation, and GH secretion across four decades of research [23][24].

**What are the benefits of DSIP peptide?**
Research has documented sleep quality improvement in four controlled human insomnia trials [1][3][4][5], pain reduction in a seven-patient pilot study [18], high response rates in opiate and alcohol withdrawal cohorts (97% and 87% respectively, n=107) [16], GH secretion stimulation in rodent models [7], and neuroprotective and lifespan effects in mouse aging studies [25].

**Does DSIP help you sleep?**
Four controlled human studies document consistent improvement in sleep in chronic insomniacs. Bes et al. (1992) found higher sleep efficiency and shorter sleep latency vs. placebo in 16 patients at 25 nmol/kg IV [1]. Notably, a daytime dose in one study improved the following night's sleep rather than acting as a direct sedative [2] — consistent with a circadian entrainment mechanism.

**What are the side effects of DSIP peptide?**
Human trial literature reports few adverse effects. The 107-patient withdrawal cohort found good tolerance with occasional headache as the only notable side effect [16]. The seven-night insomnia trial found no adverse events and daytime performance improvement [3]. Robust long-term human safety data does not exist.

**How long does it take for DSIP peptide to work?**
In the acute IV insomnia study, sleep benefit appeared beginning in the second hour post-injection [2]. In the seven-night trial, improvement was observed from the first treatment night [3]. Daytime administration may improve the following night's sleep rather than acting acutely [2].

**Does DSIP really work?**
The strongest human evidence is the Bes et al. (1992) double-blind study (PMID 1299794, n=16) showing statistically significant improvement in sleep efficiency vs. placebo [1]. Three additional controlled insomnia studies report consistent directional benefit [2][3][4]. The evidence base is small and concentrated in one research era; no Phase III trial has been completed.

**Does DSIP increase delta wave sleep without suppressing REM sleep?**
Yes, in both animal and human data. EEG analysis in rats showed selective amplification of delta/theta activity up to eleven hours post-administration without disrupting REM architecture [14]. The acute human study found a modest increase in REM alongside sleep improvement [2].

**Can DSIP cross the blood-brain barrier?**
Yes — confirmed in vascularly perfused guinea pig brain via a high-affinity saturable transport mechanism, with competitive inhibition by L-tryptophan (DSIP's N-terminal residue) [10]. CSF penetration of DSIP analogs in dogs correlated strongly with plasma concentration, half-life, and lipophilicity (r=0.813, p<0.00005) [12].

**What is the half-life of DSIP?**
Free DSIP plasma half-life is 2-4 minutes across species (2.0 min in rat, 2.9 min in monkey, 4.0 min in dog) [11]. Despite this, in-vivo effects last hours to days. Carrier protein binding and downstream neuroendocrine cascades are proposed explanations.

**Does DSIP cause dependence?**
No physical dependence has been reported in published human trials. DSIP does not appear to act on GABA-A receptors. No withdrawal syndrome has been described in any published study following cessation.

**Is DSIP a sleeping pill?**
No. DSIP is a naturally occurring neuropeptide, not a sedative or hypnotic. It appears to modulate sleep architecture via circadian and neuroendocrine pathways rather than directly inducing sedation [2].

**Does DSIP cause rebound insomnia when discontinued?**
No rebound insomnia has been reported in any published trial. The seven-night insomnia study found sleep improvements persisting after the treatment course ended [3]. The ten-injection study reported benefit at three-to-seven-month follow-up [4].

**Why has no one found DSIP's gene, receptor, or precursor protein?**
Despite four decades of research, a dedicated DSIP receptor and a DSIP precursor gene remain unidentified. Kovalzon and Strekalova's 2006 review characterized this as "a still unresolved riddle" [24]. The authors propose DSIP may act through multiple low-affinity receptor interactions.

## References

[1] https://pubmed.ncbi.nlm.nih.gov/1299794/
[2] https://pubmed.ncbi.nlm.nih.gov/7028502/
[3] https://pubmed.ncbi.nlm.nih.gov/3622582/
[4] https://pubmed.ncbi.nlm.nih.gov/6391926/
[10] https://pubmed.ncbi.nlm.nih.gov/2547200/
[11] https://pubmed.ncbi.nlm.nih.gov/6379493/
[12] https://pubmed.ncbi.nlm.nih.gov/3768731/
[14] https://pubmed.ncbi.nlm.nih.gov/11214497/
[16] https://pubmed.ncbi.nlm.nih.gov/6548969/
[24] https://pubmed.ncbi.nlm.nih.gov/16539679/

---

Nine residues, twenty-five studies, one grid — the DSIP peptide research record indexed by finding, not by vendor.